Recombinant Topoisomerase II alpha anticorps (AA 1352-1493)

N° du produit ABIN7870548

L’anticorps anti-Topoisomerase II alpha Monoclonal Souris est utilisé pour la détection de Topoisomerase II alpha dans des échantillons de Humain et Souris. Il a été validé pour WB et IHC (p).

Aperçu rapide pour Recombinant Topoisomerase II alpha anticorps (AA 1352-1493) (ABIN7870548)

Antigène: Topoisomerase II alpha (TOP2A) (Topoisomerase (DNA) II alpha 170kDa (TOP2A))

Type d'anticorp: Recombinant Antibody

Reactivité: Humain, Souris

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp Topoisomerase II alpha est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: RTOP2A-6569

Détail du produit anti-Topoisomerase II alpha anticorps

Épitope: AA 1352-1493

Fonction: Recombinant TOP2A Antibody / Topoisomerase II alpha

Purification: Protein A/G affinity

Immunogène: A portion of amino acids 1352-1493 was used as the immunogen for the recombinant TOP2A antibody.

Isotype: IgG2a, kappa

Information d'application

Indications d'application: Optimal dilution of the recombinant TOP2A antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Aliquot the recombinant TOP2A antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Détails sur Topoisomerase II alpha

Antigène: Topoisomerase II alpha (TOP2A) (Topoisomerase (DNA) II alpha 170kDa (TOP2A))

Autre désignation: TOP2A

Sujet: It recognizes a 170 kDa protein, which is identified as topoisomerase II is also implicated in drug resistance of tumor cells and has been shown to be over-expressed in many human cancers. Decreased expression of Topo IIa is the predominant mechanism of resistance to several chemotherapeutic agents.

UniProt: P11388

Pathways: Cycle Cellulaire, Mitotic G1-G1/S Phases